ZAI LAB(ZLAB) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $100.1 million for the second quarter of 2024, representing 45% y-o-y growth; 47% y-o-y growth at constant exchange rate (CER) – VYVGART (efgartigimod alfa injection) sales of$ 23.2 million for the second quarter of 2024; raising full-year VYVGART revenue guidance to exceed $80.0 million ® – Expansion of Zai Lab's global oncology pipeline with a next generation ROR1 antibody-drug conjug ...